Emily L Joyce1,2,3, Sandra L Kane-Gill2,4,5,6, Priyanka Priyanka2,3, Dana Y Fuhrman7,2,3,6, John A Kellum2,3,6. 1. Division of Nephrology, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; emilylaurenjoyce@gmail.com. 2. Department of Critical Care Medicine, Center for Critical Care Nephrology. 3. Department of Critical Care Medicine, CRISMA Center (Clinical Research, Investigation, and Systems Modeling of Acute Illness), and. 4. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania; and. 5. Department of Pharmacy, UPMC, Pittsburgh, Pennsylvania. 6. Department of Critical Care Medicine, UPMC University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 7. Division of Nephrology, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: There continues to be uncertainty about whether piperacillin/tazobactam (TZP) increases the risk of AKI in critically ill pediatric patients. We sought to compare rates of AKI among critically ill children treated with TZP or cefepime, an alternative frequently used in intensive care units, with and without vancomycin. METHODS: We conducted a retrospective cohort study assessing the risk of AKI in pediatric intensive care unit patients after exposure to vancomycin, TZP, and cefepime, alone or in combination, within 48 hours of admission. The primary outcome was development of stage 2 or 3 AKI or an increase in AKI stage from 2 to 3 within the 6 days after the 48-hour exposure window. Secondary outcomes included lengths of stay, need for RRT, and mortality. RESULTS: Of 5686 patients included, 494 (8.7%) developed stage 2 or 3 AKI. The adjusted odds of developing AKI after medication exposure were 1.56 for TZP (95% confidence interval [95% CI], 1.23 to 1.99), 1.13 for cefepime (95% CI, 0.79 to 1.64), and 0.86 for vancomycin (95% CI, 0.69 to 1.07). The adjusted odds of developing AKI for vancomycin plus TZP versus vancomycin plus cefepime was 1.38 (95% CI, 0.85 to 2.24). CONCLUSIONS: Observational data in critically ill children show that TZP use is associated with increased odds of AKI. A weaker, nonsignificant association between vancomycin plus TZP and AKI compared with vancomycin plus cefepime, creates some uncertainty about the nature of the association between TZP and AKI. However, cefepime is an alternative not associated with AKI.
BACKGROUND: There continues to be uncertainty about whether piperacillin/tazobactam (TZP) increases the risk of AKI in critically ill pediatric patients. We sought to compare rates of AKI among critically ill children treated with TZP or cefepime, an alternative frequently used in intensive care units, with and without vancomycin. METHODS: We conducted a retrospective cohort study assessing the risk of AKI in pediatric intensive care unit patients after exposure to vancomycin, TZP, and cefepime, alone or in combination, within 48 hours of admission. The primary outcome was development of stage 2 or 3 AKI or an increase in AKI stage from 2 to 3 within the 6 days after the 48-hour exposure window. Secondary outcomes included lengths of stay, need for RRT, and mortality. RESULTS: Of 5686 patients included, 494 (8.7%) developed stage 2 or 3 AKI. The adjusted odds of developing AKI after medication exposure were 1.56 for TZP (95% confidence interval [95% CI], 1.23 to 1.99), 1.13 for cefepime (95% CI, 0.79 to 1.64), and 0.86 for vancomycin (95% CI, 0.69 to 1.07). The adjusted odds of developing AKI for vancomycin plus TZP versus vancomycin plus cefepime was 1.38 (95% CI, 0.85 to 2.24). CONCLUSIONS: Observational data in critically ill children show that TZP use is associated with increased odds of AKI. A weaker, nonsignificant association between vancomycin plus TZP and AKI compared with vancomycin plus cefepime, creates some uncertainty about the nature of the association between TZP and AKI. However, cefepime is an alternative not associated with AKI.
Authors: Dennis Bailey; Véronique Phan; Catherine Litalien; Thierry Ducruet; Aicha Mérouani; Jacques Lacroix; France Gauvin Journal: Pediatr Crit Care Med Date: 2007-01 Impact factor: 3.624
Authors: Megan K Luther; Tristan T Timbrook; Aisling R Caffrey; David Dosa; Thomas P Lodise; Kerry L LaPlante Journal: Crit Care Med Date: 2018-01 Impact factor: 7.598
Authors: Scott M Sutherland; John J Byrnes; Manish Kothari; Christopher A Longhurst; Sanjeev Dutta; Pablo Garcia; Stuart L Goldstein Journal: Clin J Am Soc Nephrol Date: 2015-02-03 Impact factor: 8.237
Authors: Brandon P Mullins; C Joseph Kramer; Billie J Bartel; Jennifer S Catlin; Richard E Gilder Journal: Ann Pharmacother Date: 2018-02-14 Impact factor: 3.154
Authors: Marlies Ostermann; Peter A McCullough; Lui G Forni; Sean M Bagshaw; Michael Joannidis; Jing Shi; Kianoush Kashani; Patrick M Honore; Lakhmir S Chawla; John A Kellum Journal: Crit Care Med Date: 2018-03 Impact factor: 7.598
Authors: Mohamed O Saad; Adham M Mohamed; Hassan A Mitwally; Ahmed A Shible; Ali Ait Hssain; Mohamed A Abdelaty Journal: Infection Date: 2020-07-22 Impact factor: 3.553